RCT: Effectiveness of Fosfomycin for treating multidrug-resistant Escherichia coli bacteremic urinary tract infections.

Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections: A Randomized Clinical Trial – JAMA Network Open

Commentaries:

The Role of Intravenous Fosfomycin: Finding Our Way Out of Dante’s Forest Dark – JAMA Network Open

Fosfomycin Not Noninferior to Comparators for Bacteremic UTI – HealthDay

‘Forgotten’ antibiotic recovered for resistant bacterial infections – University of Seville

Commentary on Twitter

In this RCT, fosfomycin did not demonstrate noninferiority in MDR-E coli bacteremic UTI, mostly due to adverse event-related withdrawals in mITT, but showed efficacy in per protocol analysis. #FORESTtrial @jesusrbano https://t.co/oiPtiQo2XA pic.twitter.com/Q44QQb18cN

— JAMA Network Open (@JAMANetworkOpen) January 13, 2022